2021 DORIS definition of remission in SLE: final recommendations from an international task force

Vista sencilla de ítem
dc.date.accessioned2023-04-05T12:45:47Z
dc.date.available2023-04-05T12:45:47Z
dc.date.issued2021
dc.description.abstractObjective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies. © 2021 BMJ Publishing Group. All rights reserved.
dc.identifier.issn20538790
dc.identifier.urihttps://doi.org/10.1136/lupus-2021-000538
dc.identifier.urihttp://146.190.124.33/handle/123456789/5825
dc.language.isoenges_ES
dc.publisherBMJ Publishing Groupes_ES
dc.sourceRevista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 15 Núm. 2
dc.title2021 DORIS definition of remission in SLE: final recommendations from an international task forcees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersion
Archivos
Colecciones
Revisión